Paylaş
))
Bill Nye is on a mission to change the world — one voicemail at a time. Bill and science writer Corey S. Powell take your burning questions and put them to the world's leading experts on just about every topic in the universe. Should you stop eating cheeseburgers to combat climate change? Could alien life be swimming inside the moons of Jupiter and Saturn? Does your pet parakeet learn to sing the way that you learned to speak? Bill, Corey, and their special guests will answer those questions ...
…
continue reading
Gerald Appel, MD, PhD - Targeted Complements: Exploring New Horizons Designed to Address Gaps in Treating Complement-Associated Kidney Diseases
Manage episode 354280350 series 1157776
İçerik PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
Go online to PeerView.com/FSW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Explore new horizons in complement-targeted treatments with two leading experts who share fresh insights into the underlying pathophysiology of complement-associated kidney diseases and provide evidence-based guidance on their diagnosis and treatment. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of complement-associated kidney diseases, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets; Differentially diagnose patients with complement-associated kidney diseases in a timely manner using evidence-based tools and strategies; and Describe current and emerging treatments for complement-associated kidney diseases, including data from recent clinical trials.
…
continue reading
52 bölüm
